APR 15, 2018 3:27 AM PDT

Monoclonal Antibody May Serve as Treatment for Malaria

WRITTEN BY: Nouran Amin

A study published in Nature Medicine examines a monoclonal antibody isolated from the blood of individuals vaccinated for malaria and its potential role in preventing infection from tropical diseases.

Malaria is a life-threatening blood disease that is caused by the Plasmodium parasite and transmitted to humans through Anopheles mosquito bite.

After an infected mosquito bites a human, the parasites will multiply in the host's liver where it can infect and destroy red blood cells. Ina few places, malaria can be treated and controlled under early diagnosis, however, not all countries have the resources to do this effectively. At the present moment, no vaccine has been approved for use in the United States or globally, although one is licensed in Europe. Now, only a single malaria vaccine, known as RTS,S, has moved on to Phase 3 clinical trials.

 

The goal was to identify a binding site on circumsporozoite (CSP), which is a protein found on the surface of the malaria parasite. The antibody that was identified was CIS43 and it’s believed thought that it could be of protection from malaria for up to six months, which shows improvement over existing preventative malarial drugs.

 

The researched team began their studies by testing the blood of individuals immunized with an experimental malaria vaccine, PfSPZ, which includes weakened malarial parasites. The blood test resulted in the identification of the antibody in question, CIS43 which “conferred high-level, sterile protection in two different mouse models of malaria infection,” noted the authors in their study “The affinity and stoichiometry of CIS43 binding to PfCSP indicate that there are two sequential multivalent binding events encompassing the repeat domain. The first binding event is to a unique 'junctional' epitope positioned between the N terminus and the central repeat domain of PfCSP. Moreover, CIS43 prevented proteolytic cleavage of PfCSP on PfSPZ. Analysis of crystal structures of the CIS43 antigen-binding fragment in complex with the junctional epitope determined the molecular interactions of binding, revealed the epitope's conformational flexibility and defined Asn-Pro-Asn (NPN) as the structural repeat motif.”

 

 

“The group used excellent structural and biophysical methods to analyze the binding of the antibody to the protein target in order to explain the antibodies’ neutralizing capacity,” explained Dr. Sean Murphy designer of the diagnostic tool used in the research study. “This is a big deal because neutralizing monoclonal antibodies have transformed the approach to HIV, and the possibility exists that they will do the same for malaria,” he added.

 

It is important to note that these studies where performed on animal models. Investigators hope that they can take these studies and move them a step up for a 2019 clinical trial.

 

Sources: Medical News Today, Drug Discovery News

About the Author
BS/MS
Nouran is a scientist, educator, and life-long learner with a passion for making science more communicable. When not busy in the lab isolating blood macrophages, she enjoys writing on various STEM topics.
You May Also Like
MAY 06, 2022
Drug Discovery & Development
Scientists discover new methods of production for Sulphur-based medications
MAY 06, 2022
Scientists discover new methods of production for Sulphur-based medications
Modern medicine has drastically changed since humans discovered the first ancient treatment methods. Herbal remedies and ...
MAY 12, 2022
Drug Discovery & Development
Gut Bacteria Composition Predicts Resposnse to Statins
MAY 12, 2022
Gut Bacteria Composition Predicts Resposnse to Statins
The composition of the gut microbiome is predictive of patient responses to statins. The corresponding study was publish ...
JUN 07, 2022
Health & Medicine
Drug that lowers blood sugar also reduces blood vessel dysfunction caused by aging
JUN 07, 2022
Drug that lowers blood sugar also reduces blood vessel dysfunction caused by aging
Cardiovascular diseases (CVDs) are the leading cause of death globally, taking an estimated 17.9 million lives ...
JUN 08, 2022
Coronavirus
How are you Preparing for the Next Covid Surge?
JUN 08, 2022
How are you Preparing for the Next Covid Surge?
After two years of uncertainty, we can definitely say that the coronavirus (Covid-19) has changed our everyday lives as ...
JUN 13, 2022
Cancer
Clinical Trial Demonstrates an Amazing 100% Response
JUN 13, 2022
Clinical Trial Demonstrates an Amazing 100% Response
The results of a Clinical Trial for rectal cancer patients published last week in the New England Journal of Medicine co ...
JUN 27, 2022
Plants & Animals
Developing a New Approach to Rabies Vaccination
JUN 27, 2022
Developing a New Approach to Rabies Vaccination
Rabies is a viral disease that can spread through the saliva. Several kinds of animals can get rabies, including humans ...
Loading Comments...